Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain zaps aim to help Parkinson's patients walk steadier

NCT ID NCT02931097

Symptom relief Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether deep brain stimulation of a specific brain region could improve walking and balance in people with advanced Parkinson's disease. Six participants received both real and sham stimulation in a blinded crossover design. The goal was to see if this approach could help with symptoms that don't respond to standard medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
deep brain stimulation
What this could lead to
If it works, this could point toward a treatment for gait and balance problems in advanced Parkinson's disease that don't respond to standard medication.
What could go wrong
This is a very small, early study with only 6 participants, so results may not apply to everyone. The treatment involves brain surgery, which carries risks like infection or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

6 people

The number who actually took part.

Started

Oct 2016

Finished

Oct 2020

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 71 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age below 71 years * severe form of Parkinson's Disease with disease duration \> 5 years * presence of gait and/or balance disorders unresponsive to levodopa treatment, * \> 40% decrease in others motor symptoms with levodopa treatment * health insurance * give signed informed written consent Exclusion Criteria: * dementia (Mattis Dementia Rating Scale \< 129, MDRS), * ongoing psychiatric disturbances, * surgical contraindications * significant brain lesions detected on MRI.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease

Contacts and locations

Locations

  • Centre d'Investigation Clinique-Institut du Cerveau et de la Moelle Epiniere

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.